Almirall SA ((GB:0O9B)), Almirall ((DE:E2Z)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Almirall S.A. is conducting a study titled ‘Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting – Light Version.’ The study aims to explore the connection between clinical symptoms and quality of life in patients with moderate to severe plaque psoriasis treated with Tildrakizumab, a drug administered in routine clinical settings.
The intervention being tested is Tildrakizumab, a drug designed to treat moderate to severe plaque psoriasis. It is used in real-world clinical practice to assess its impact on patient wellbeing and quality of life.
This observational study follows a cohort model with a prospective time perspective. It does not involve random allocation or masking, focusing instead on observing the outcomes of patients receiving the drug in a real-world setting.
The study began on April 4, 2024, with the primary completion date yet to be announced. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The update on this study could influence Almirall’s stock performance and investor sentiment, as successful results may enhance the company’s market position in the psoriasis treatment sector. Investors should also consider the competitive landscape, as advancements in psoriasis treatments are ongoing across the industry.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.